Individuals taking steroid tablets for more than 3 months are over 6 times more likely to be diagnosed with adrenal ...

Mepolizumab added to triple therapy improves exacerbation outcomes in moderate to severe COPD and is effective to 2 years of ...

The study evaluated 807 adults who initiated an anti–IL–5 therapy (79% mepolizumab, 21% benralizumab) between 2017 and 2020.

Eucalyptus oil might be at or near the top of the essential oils list for these patients, given its storied history in both ...

M. Bradley Drummond, MD, MHS, professor of medicine, University of North Carolina at Chapel Hill, shares promising results of ensifentrine in helping patients with insufficient chronic obstructive ...

AstraZeneca presented data from the phase 3 BATURA study which showed that use of Airsupra in those with mild asthma reduced ...

Late-breaking findings on pulmonology, critical care, and sleep medicine will be presented at the American Thoracic Society (ATS) 2025 International Conference.

For World Asthma Day, GINA released its 2025 guidelines update and joined in a campaign to make inhaled asthma therapies more ...

Treatment with steroid tablets for longer than three months has been shown to increase the likelihood of diagnosis with adrenal insufficiency (AI) by more than six times when compared with those ...

Corticosteroids are used to treat a wide range of conditions, including asthma, allergies, eczema, and inflammatory bowel ...

The Health Sciences Authority (HSA) has approved Dupixent (dupilumab) for adults as an add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) characterized by ...